RGNX PE Ratio & Valuation,Is RGNX Overvalued

RGNX Relative Valuation

RGNX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RGNX is overvalued; if below, it's undervalued.

Historical Valuation

Regenxbio Inc (RGNX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.89 is considered Undervalued compared with the five-year average of 2.79. The fair price of Regenxbio Inc (RGNX) is between 16.96 to 43.88 according to relative valuation methord. Compared to the current price of 14.18 USD , Regenxbio Inc is Undervalued By 16.39%.

Relative Value

Fair Zone

16.96-43.88

Current Price：14.18

16.39%

Undervalued

-4.94

73.60

EV/EBITDA

Regenxbio Inc. (RGNX) has a current EV/EBITDA of 73.60. The 5-year average EV/EBITDA is -1.00. The thresholds are as follows: Strongly Undervalued below -30.90, Undervalued between -30.90 and -15.95, Fairly Valued between 13.95 and -15.95, Overvalued between 13.95 and 28.90, and Strongly Overvalued above 28.90. The current Forward EV/EBITDA of 73.60 falls within the Strongly Overvalued range.

-6.63

EV/EBIT

Regenxbio Inc. (RGNX) has a current EV/EBIT of -6.63. The 5-year average EV/EBIT is -5.68. The thresholds are as follows: Strongly Undervalued below -26.14, Undervalued between -26.14 and -15.91, Fairly Valued between 4.55 and -15.91, Overvalued between 4.55 and 14.78, and Strongly Overvalued above 14.78. The current Forward EV/EBIT of -6.63 falls within the Historic Trend Line -Fairly Valued range.

2.89

Regenxbio Inc. (RGNX) has a current PS of 2.89. The 5-year average PS is 5.83. The thresholds are as follows: Strongly Undervalued below -1.05, Undervalued between -1.05 and 2.39, Fairly Valued between 9.26 and 2.39, Overvalued between 9.26 and 12.70, and Strongly Overvalued above 12.70. The current Forward PS of 2.89 falls within the Historic Trend Line -Fairly Valued range.

9.95

P/OCF

Regenxbio Inc. (RGNX) has a current P/OCF of 9.95. The 5-year average P/OCF is -7.98. The thresholds are as follows: Strongly Undervalued below -77.60, Undervalued between -77.60 and -42.79, Fairly Valued between 26.83 and -42.79, Overvalued between 26.83 and 61.65, and Strongly Overvalued above 61.65. The current Forward P/OCF of 9.95 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Regenxbio Inc. (RGNX) has a current P/FCF of 0.00. The 5-year average P/FCF is 1.53. The thresholds are as follows: Strongly Undervalued below -116.46, Undervalued between -116.46 and -57.46, Fairly Valued between 60.52 and -57.46, Overvalued between 60.52 and 119.52, and Strongly Overvalued above 119.52. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Regenxbio Inc (RGNX) has a current Price-to-Book (P/B) ratio of 4.25. Compared to its 3-year average P/B ratio of 2.03 , the current P/B ratio is approximately 109.65% higher. Relative to its 5-year average P/B ratio of 2.21, the current P/B ratio is about 92.21% higher. Regenxbio Inc (RGNX) has a Forward Free Cash Flow (FCF) yield of approximately -15.47%. Compared to its 3-year average FCF yield of -30.04%, the current FCF yield is approximately -48.50% lower. Relative to its 5-year average FCF yield of -17.14% , the current FCF yield is about -9.73% lower.

4.25

P/B

Median3y

2.03

Median5y

2.21

-15.47

FCF Yield

Median3y

-30.04

Median5y

-17.14

Competitors Valuation Multiple

The average P/S ratio for RGNX's competitors is 6.74, providing a benchmark for relative valuation. Regenxbio Inc Corp (RGNX) exhibits a P/S ratio of 2.89, which is -57.04% above the industry average. Given its robust revenue growth of 22.88%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of RGNX increased by 75.71% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.33 to -3.92.

The secondary factor is the Revenue Growth, contributed 22.88%to the performance.

Overall, the performance of RGNX in the past 1 year is driven by P/E Change. Which is more unsustainable.

22.88%

24.20M → 29.73M

Revenue Growth

-15.42%

-246.30 → -208.32

Margin Expansion

68.25%

-2.33 → -3.92

P/E Change

75.71%

8.07 → 14.18

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Regenxbio Inc (RGNX) currently overvalued or undervalued?

What is Regenxbio Inc (RGNX) fair value?

RGNX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Regenxbio Inc (RGNX) is between 16.96 to 43.88 according to relative valuation methord.

How does RGNX's valuation metrics compare to the industry average?

What is the current P/B ratio for Regenxbio Inc (RGNX) as of Jan 08 2026?

As of Jan 08 2026, Regenxbio Inc (RGNX) has a P/B ratio of 4.25. This indicates that the market values RGNX at 4.25 times its book value.

What is the current FCF Yield for Regenxbio Inc (RGNX) as of Jan 08 2026?

As of Jan 08 2026, Regenxbio Inc (RGNX) has a FCF Yield of -15.47%. This means that for every dollar of Regenxbio Inc’s market capitalization, the company generates -15.47 cents in free cash flow.

What is the current Forward P/E ratio for Regenxbio Inc (RGNX) as of Jan 08 2026?

As of Jan 08 2026, Regenxbio Inc (RGNX) has a Forward P/E ratio of -4.94. This means the market is willing to pay $-4.94 for every dollar of Regenxbio Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Regenxbio Inc (RGNX) as of Jan 08 2026?

As of Jan 08 2026, Regenxbio Inc (RGNX) has a Forward P/S ratio of 2.89. This means the market is valuing RGNX at $2.89 for every dollar of expected revenue over the next 12 months.

RGNX Valuation

Overview

Forecast

Valuation

Earnings